Metalloproteinase-1, metalloproteinase-7, and p53 immunoexpression and their correlation with clinicopathological prognostic factors in colorectal adenocarcinoma

International Journal of Biological Markers

Volumn 24, Issue 3, 2009, Pages 156-164

  Nunes, Benicio L B B P ^a,f   Jucá, Mário J ^b   Gomes, Edmundo G A ^b   Menezes, Hunaldo L ^c   Costa, Henrique O ^d   Matos, Delcio ^e   Saad, Sarhan S ^e  

^a Department of Internal Medicine   (Brazil)

^b FEDERAL UNIVERSITY OF ALAGOAS   (Brazil)

^c Hospital Arthur Ramos   (Brazil)

^d State University of Health Sciences of Alagoas (UNCISAL)   (Brazil)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f NONE   (Brazil)

Author keywords

Colorectal carcinoma; Metalloproteinase 1; Metalloproteinase 7; p53; Prognosis

Indexed keywords

INTERSTITIAL COLLAGENASE; MATRILYSIN; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 70449345877     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2009.4152     Document Type: Article

References (69)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 200. CA Cancer J Clin 2000; 50: 7-33.
2. Ricchi P, Pignata S, Iaffaioli RV, Danieli B. Cyclo-oxygenase inhibition in colorectal adenomas and cancer. J Clin Gastroenterol 2003; 37: 281-7.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Sanborn R, Blanke CD. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust? Semin Oncol 2005; 32: 69-75.
5. Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-60.
6. Barozzi C, Ravaioli M, D'errico A, et al. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002; 94: 647-57.
7. Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers 2007; 22 (Suppl 4): 40-6.
8. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvliet N, O'Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996; 20: 1260-5.
9. Tanigawa N, Amaya H, Matsumura M, et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 1997; 57: 1043-6.
10. Choi HJ, Hyun MS, Jung GJ, Kim SS, Hong SH. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998; 55: 575-81.
11. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. New Engl J Med 1998, 339: 223-8.
12. Berney CR, Fisher RJ, Yang J, Russell PJ, Crowe PJ. Protein markers in colorectal cancer: predictors of liver metastasis. Ann Surg 1999; 230: 179-84.
13. Cascinu S, Staccioli MP, Gasparini G,. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000; 6: 2803-7.
14. Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36: 748-53.
15. Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003; 9: 1990-4.
16. Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M, Zhou YF. Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance. World J Gastroenterol 2005; 1: 1105-8.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
18. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004; 23: 101-17.
19. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-64.
20. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004; 23: 119-35.
21. Jucá M, Nunes BL, Menezes HL, Gomes EG, Matos D. Metaloproteinases 1 e 7 e câncer colorretal. Rev Bras Coloproct 2008; 28: 353-62.
22. Gomes EG. Análise das expressões imunohistoquímicas da metaloproteinase-1, metaloproteinase-7 e do fator de crescimento endotelial vascular no adenocarcinoma colorretal e suas correlações com os fatores prognósticos [tese]. São Paulo: Universidade Federal de São Paulo; 2008.
23. Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000; 5: 108-14.
24. Nosho K, Yoshida M, Yamamoto H, et al. Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis. Carcinogenesis 2005; 26: 892-9.
25. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
26. Hasegawa S, Koshikawa N, Momiyama N, et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998; 76: 812-6.
27. Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 2003; 22: 8662-70.
28. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996; 28: 123-36.
29. Ichikawa Y, Ishikawa T, Momiyama N, et al. Detection of regional lymph node metastases in colon cancer using RTPCR for matrix metalloproteinase 7, matrilysin. Clin Exp Metastasis 1998; 16: 3-8.
30. Masaki T, Matsuoka H, Sugiyama M, Abe N, Goto A, Sakamoto A, Atomi Y. Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 2001; 84: 1317-21.
31. Yanagisawa N, Geironson L, Al-Soud WA, Ljungh A. Expression of matrix metalloproteinase-2, -7 and -9 on human colon, liver and bile duct cell lines by enteric and gastric helicobacter species. FEMS Immunol Med Microbiol 2005; 44: 197-204.
32. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57: 1-9.
33. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
34. Rocha FT, Lourenço LG, Jucá MJ, Leal AT, Paz AM. Expressão da proteína p53 no adenocarcinoma gástrico: correlação clínica, anatomopatológica e significância prognóstica. Rev Col Bras Cir 2004; 31: 186-93.
35. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005; 16 (Suppl 4): 44-9.
36. Mills AA. P53: link to the past, bridge to the future. Genes Dev 2005; 19: 2091-9.
37. Hofseth LJ, Hussain SP, Harris CC. P53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-81.
38. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-15.
39. Watson AJ. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006; 57: 107-21.
40. Oren M, Rotter V. Introduction: p53 - the first twenty years. Cell Mol Life Sci 1999; 55: 9-11.
41. Bulloch AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1: 68-76.
42. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol 2006; 41: 185-92.
43. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
44. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
45. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005; 92: 434-44.
46. Lustosa SA, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras 2005; 20: 353-7.
47. Dowell SP, Hall PA. The p53 tumour suppressor gene and tumour prognosis: is there a relationship? J Pathol 1995; 177: 221-4.
48. Brown PD. Matrix metalloproteinases in gastrointestinal cancer. Gut 1998; 43: 161-3.
49. Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1,-2, -7 and 13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007; 121: 714-23.
50. Bendardaf R, Buhmeida A, Ristamäki R, Syrjänen K, Pyrhönen S. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol 2007; 42: 1473-8.
51. Cohen T, Prus D, Shia J, et al. Expression of p53, p27 and Ki-67 in colorectal cancer patients of various ethnic origins: clinical and tissue microarray based analysis. J Surg Oncol 2008; 97: 416-22.
52. Lyall MS, Dundas SR, Curran S, Murray GI. Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12: 1184-91.
53. Bendardaf R, Lamlum H, Vihinen P, Ristamäki R, Laine J, Pyrhönen S. Low-collagenase-1 (MMP-1) and MT1-MMP expression levels are favourable survival markers in advanced colorectal carcinoma. Oncology 2003; 65: 337-46.
54. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461-2.
55. Bennett MA, Kay EW, Mulcahy H, et al. Ras and p53 in the prediction of survival in Dukes's stage B colorectal carcinoma. Clin Mol Pathol 1995, 48: M310-5.
56. Bouzourene H, Gervaz P, Cerottini JP, et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal Cancer. Eur J Cancer 2000; 36: 1008-15.
57. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 2004; 10: 8229-34.
58. Hong-Zhi L, Zong-Guang Z, Lie Y, et al. Clinicopathologic and prognostic significance of MMP-7 (Matrilysin) expression in human rectal cancer. Jpn J Clin Oncol 2005; 35: 739-44.
59. Schwandner O, Schlamp A, Broll R, Bruch HP. Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer. Int J Colorectal Dis 2007; 22: 127-36.
60. van der Stappen JW, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 1990; 45: 1071-8.
61. Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol 2000; 13: 925-33.
62. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999; 45: 252-8.
63. Zinzindohoué F, Lecomte T, Ferraz JM, et al. Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005; 11: 594-9.
64. Roeb E, Arndt M, Jansen B, Schumpelick V, Matern S. Simultaneous determination of matrix metalloproteinase (MMP)-7, MMP-1, -3, and -13 gene expression by multiplex PCR in colorectal carcinomas. Int J Colorectal Dis 2004; 19: 518-24.
65. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003; 200: 568-76.
66. Baker EA, Bergin FG, Leaper DJ. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br J Surg 2000; 87: 1215-21.
67. Georgieva M, Krasteva M, Angelova E, et al. Analysis of the K-ras/B-raf/ Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. Oncol Rep 2008; 20: 2-11.
68. Lustosa SA. O valor prognóstico e a correlação histopatológica das proteínas p53 e Bcl-2 em doentes portadores de adenocarcinoma colorretal, submetidos ao tratamento cirúrgico [tese]. São Paulo: Universidade Federal de São Paulo; 2003.
69. Paradiso A, Volpe S, Iacobacci A, et al; Italian Network for Quality Assessment of Tumor Biomarkers. Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers 2002; 17: 201-14.